Get the app
public
ios_share
OncoPharm
chevron_right
Zongertinib
Aug 14, 2025
12:07
forum
Ask episode
play_arrow
Play
view_agenda
Chapters
auto_awesome
Transcript
info_circle
Episode notes
A new ERBB2 (HER2) targeting TKI is approved for NSCLC. We review the characteristics of the drug and summarize the current landscape in treating HER-mutated advanced NSCLC.
